ImmunoCellular Therapeutics, Ltd Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis
6/7/2013 10:42:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.
Help employers find you! Check out all the jobs and post your resume.
comments powered by